{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:35Z","timestamp":1790677415667,"version":"4.1.0"},"reference-count":140,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12035-019-01820-5","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T08:03:46Z","timestamp":1573545826000},"page":"1259-1280","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Molecular Approaches for the Treatment of Pompe Disease"],"prefix":"10.1007","volume":"57","author":[{"given":"Anita Sofia","family":"Bellotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Andreoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Ronchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nereo","family":"Bresolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo P.","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-969X","authenticated-orcid":false,"given":"Stefania","family":"Corti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"1820_CR1","volume-title":"A CME monograph","author":"PS Kishnani","year":"2017","unstructured":"Kishnani PS, Berger KI, Carter GT, Case LE (2017) Late-onset Pompe disease presentation, diagnosis, and management. In: A CME monograph"},{"issue":"4","key":"1820_CR2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1002\/mus.21025","volume":"38","author":"JHJ Wokke","year":"2008","unstructured":"Wokke JHJ, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg L, Florence JM, Mayhew J et al (2008) Clinical features of late-onset pompe disease: a prospective cohort study. Muscle Nerve. 38(4):1236\u20131245. https:\/\/doi.org\/10.1002\/mus.21025","journal-title":"Muscle Nerve."},{"issue":"3","key":"1820_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","volume":"120","author":"J Chan","year":"2017","unstructured":"Chan J, Desai AK, Kazi ZB, Corey K, Austin S, Hobson-Webb LD, Case LE, Jones HN et al (2017) The emerging phenotype of late-onset Pompe disease: a systematic literature review. Mol Genet Metab. 120(3):163\u2013172. https:\/\/doi.org\/10.1016\/j.ymgme.2016.12.004","journal-title":"Mol Genet Metab."},{"key":"1820_CR4","doi-asserted-by":"publisher","unstructured":"Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001:3389-3420. doi:https:\/\/doi.org\/10.1036\/ommbid.164","DOI":"10.1036\/ommbid.164"},{"key":"1820_CR5","first-page":"147","volume":"XXXIV","author":"B Schoser","year":"2015","unstructured":"Schoser B, Lafor\u00eat P, Kruijshaar AT ME, Ploeg PA van D and AT van der, (EPOC) on behalf of the EPC (2015) Minutes of the European POmpe Consortium (EPOC) meeting. Acta Myol XXXIV:147\u2013149 2015:141-143","journal-title":"Acta Myol"},{"issue":"13","key":"1820_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.21037\/atm.2019.05.47","volume":"7","author":"Y-H Chien","year":"2019","unstructured":"Chien Y-H, Hwu W-L, Lee N-C (2019) Newborn screening: Taiwanese experience. Ann Transl Med 7(13):281. https:\/\/doi.org\/10.21037\/atm.2019.05.47","journal-title":"Ann Transl Med"},{"key":"1820_CR7","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/1750-1172-8-182","volume":"8","author":"SCA Wens","year":"2013","unstructured":"Wens SCA, van Gelder CM, Kruijshaar ME, de Vries JM, van der Beek N, Reuser AJ, van Doorn P, van der Ploeg A et al (2013) Phenotypical variation within 22 families with Pompe disease. Orphanet J Rare Dis. 8:182. https:\/\/doi.org\/10.1186\/1750-1172-8-182","journal-title":"Orphanet J Rare Dis."},{"issue":"51","key":"1820_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009186","volume":"96","author":"M Mart\u00ednez","year":"2017","unstructured":"Mart\u00ednez M, Romero MG, Guereta LG, Cabrera M, Regojo RM, Albajara L, Couce ML, Pipaon MS (2017) Infantile-onset Pompe disease with neonatal debut: a case report and literature review. Medicine (Baltimore). 96(51):e9186. https:\/\/doi.org\/10.1097\/MD.0000000000009186","journal-title":"Medicine (Baltimore)."},{"issue":"2","key":"1820_CR9","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1542\/peds.112.2.332","volume":"112","author":"HMP van den Hout","year":"2004","unstructured":"van den Hout HMP, Hop W, van Diggelen OP et al (2004) The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics 112(2):332\u2013340. https:\/\/doi.org\/10.1542\/peds.112.2.332","journal-title":"Pediatrics"},{"issue":"9-10","key":"1820_CR10","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","volume":"17","author":"W M\u00fcller-Felber","year":"2007","unstructured":"M\u00fcller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M et al (2007) Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord. 17(9-10):698\u2013706. https:\/\/doi.org\/10.1016\/j.nmd.2007.06.002","journal-title":"Neuromuscul Disord."},{"key":"1820_CR11","unstructured":"van der Beek NAME, Hagemans MLC, van der Ploeg AT, Reuser AJJ, van Doorn PA. Pompe disease (glycogen storage disease type II): clinical features and enzyme replacement therapy. Acta Neurol Belg. 2006;106(2):82-86. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16898258. Accessed May 6, 2019."},{"issue":"3","key":"1820_CR12","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","volume":"21","author":"MP Wasserstein","year":"2019","unstructured":"Wasserstein MP, Caggana M, Bailey SM, Desnick RJ, Edelmann L, Estrella L, Holzman I, Kelly NR et al (2019) The New York pilot newborn screening program for lysosomal storage diseases: report of the first 65,000 infants. Genet Med. 21(3):631\u2013640. https:\/\/doi.org\/10.1038\/s41436-018-0129-y","journal-title":"Genet Med."},{"key":"1820_CR13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajmc.31318","volume":"68","author":"M Kroos","year":"2012","unstructured":"Kroos M, Hoogeveen-Westerveld M, Ploeg a NSV a NDER, Reuser AJJ (2012) The genotype\u2013phenotype correlation in Pompe disease. Am J Med Genet 68:59\u201368. https:\/\/doi.org\/10.1002\/ajmc.31318","journal-title":"Am J Med Genet"},{"key":"1820_CR14","doi-asserted-by":"publisher","unstructured":"Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease (review). 2017;(11). doi:https:\/\/doi.org\/10.1002\/14651858.CD011539. pub2.www.cochranelibrary.com","DOI":"10.1002\/14651858.CD011539"},{"issue":"JUL","key":"1820_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3389\/fnagi.2014.00177","volume":"6","author":"JA Lim","year":"2014","unstructured":"Lim JA, Li L, Raben N (2014) Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci 6(JUL):177. https:\/\/doi.org\/10.3389\/fnagi.2014.00177","journal-title":"Front Aging Neurosci"},{"issue":"5","key":"1820_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/nan.12414","volume":"44","author":"M Ripolone","year":"2018","unstructured":"Ripolone M, Violano R, Ronchi D, Mondello S, Nascimbeni A, Colombo I, Fagiolari G, Bordoni A et al (2018) Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). Neuropathol Appl Neurobiol. 44(5):449\u2013462. https:\/\/doi.org\/10.1111\/nan.12414","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"2","key":"1820_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL, Leslie N, Levine J et al (2007) Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology. 68(2):99\u2013109. https:\/\/doi.org\/10.1212\/01.wnl.0000251268.41188.04","journal-title":"Neurology."},{"issue":"4","key":"1820_CR18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","volume":"264","author":"B Schoser","year":"2017","unstructured":"Schoser B, Stewart A, Kanters S, Hamed A, Jansen J, Chan K, Karamouzian M, Toscano A (2017) Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis. J Neurol. 264(4):621\u2013630. https:\/\/doi.org\/10.1007\/s00415-016-8219-8","journal-title":"J Neurol."},{"issue":"6","key":"1820_CR19","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/ene.13285","volume":"24","author":"AT van der Ploeg","year":"2017","unstructured":"van der Ploeg AT, Kruijshaar ME, Toscano A, Lafor\u00eat P, Angelini C, Lachmann RH, Pascual Pascual SI, Roberts M et al (2017) European consensus for starting and stopping enzyme replacement therapy in adult patients with Pompe disease: a 10-year experience. Eur J Neurol. 24(6):768\u2013e31. https:\/\/doi.org\/10.1111\/ene.13285","journal-title":"Eur J Neurol."},{"issue":"1","key":"1820_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s13023-017-0731-0","volume":"12","author":"TA Kanters","year":"2017","unstructured":"Kanters TA, van der Ploeg AT, Kruijshaar ME, Rizopoulos D, Redekop WK, Rutten-van M\u04e7lken M, Hakkaart-van Roijen L (2017) Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease. Orphanet J Rare Dis. 12(1):179. https:\/\/doi.org\/10.1186\/s13023-017-0731-0","journal-title":"Orphanet J Rare Dis."},{"issue":"1","key":"1820_CR21","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","volume":"13","author":"R Parini","year":"2018","unstructured":"Parini R, De Lorenzo P, Dardis A et al (2018) Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy. Orphanet J Rare Dis. 13(1):32. https:\/\/doi.org\/10.1186\/s13023-018-0771-0","journal-title":"Orphanet J Rare Dis."},{"issue":"9","key":"1820_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gim.2012.44","volume":"14","author":"SN Prater","year":"2012","unstructured":"Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, Jones HN, Phornphutkul C et al (2012) The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 14(9):800\u2013810. https:\/\/doi.org\/10.1038\/gim.2012.44","journal-title":"Genet Med."},{"issue":"7","key":"1820_CR23","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.ymthe.2018.04.025","volume":"26","author":"Jeong-A Lim","year":"2018","unstructured":"Lim J-A, Sun B, Puertollano R, Raben N (May 2018) Therapeutic benefit of autophagy modulation in Pompe disease. Mol Ther. https:\/\/doi.org\/10.1016\/J.YMTHE.2018.04.025","journal-title":"Molecular Therapy"},{"issue":"9646","key":"1820_CR24","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT Van der Ploeg","year":"2008","unstructured":"Van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet. 372(9646):1342\u20131353. https:\/\/doi.org\/10.1016\/S0140-6736(08)61555-X","journal-title":"Lancet."},{"issue":"7","key":"1820_CR25","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/mt.2015.62","volume":"23","author":"G Parenti","year":"2015","unstructured":"Parenti G, Andria G, Valenzano KJ (2015) Pharmacological chaperone therapy: preclinical development, clinical translation, and prospects for the treatment of lysosomal storage disorders. Mol Ther. 23(7):1138\u20131148. https:\/\/doi.org\/10.1038\/mt.2015.62","journal-title":"Mol Ther."},{"issue":"4","key":"1820_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1373\/clinchem.2016.259036","volume":"63","author":"N Lin","year":"2017","unstructured":"Lin N, Huang J, Violante S, Orsini JJ, Caggana M, Hughes EE, Stevens C, DiAntonio L et al (2017) Liquid chromatography-tandem mass spectrometry assay of leukocyte acid \u03b1-glucosidase for post-newborn screening evaluation of Pompe disease. Clin Chem. 63(4):842\u2013851. https:\/\/doi.org\/10.1373\/clinchem.2016.259036","journal-title":"Clin Chem."},{"key":"1820_CR27","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/J.YMGMR.2017.10.009","volume":"14","author":"Y Fukuhara","year":"2018","unstructured":"Fukuhara Y, Fuji N, Yamazaki N, Hirakiyama A, Kamioka T, Seo JH, Mashima R, Kosuga M et al (2018) A molecular analysis of the GAA gene and clinical spectrum in 38 patients with Pompe disease in Japan. Mol Genet Metab Reports. 14:3\u20139. https:\/\/doi.org\/10.1016\/J.YMGMR.2017.10.009","journal-title":"Mol Genet Metab Reports."},{"issue":"1","key":"1820_CR28","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40478-017-0464-2","volume":"5","author":"J Hordeaux","year":"2017","unstructured":"Hordeaux J, Dubreil L, Robveille C, Deniaud J, Pascal Q, Dequ\u00e9ant B, Pailloux J, Lagalice L et al (2017) Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease. Acta Neuropathol Commun. 5(1):66. https:\/\/doi.org\/10.1186\/s40478-017-0464-2","journal-title":"Acta Neuropathol Commun."},{"issue":"3","key":"1820_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1042\/BJ20050364","volume":"389","author":"Y Zhu","year":"2005","unstructured":"Zhu Y, Li X, Mcvie-Wylie A et al (2005) Carbohydrate-remodelled acid \u03b1-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochem J. 389(3):619\u2013628. https:\/\/doi.org\/10.1042\/BJ20050364","journal-title":"Biochem J."},{"issue":"6","key":"1820_CR30","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/mt.2009.37","volume":"17","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Jiang J-L, Gumlaw NK, Zhang J, Bercury SD, Ziegler RJ, Lee K, Kudo M et al (2009) Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease. Mol Ther. 17(6):954\u2013963. https:\/\/doi.org\/10.1038\/mt.2009.37","journal-title":"Mol Ther."},{"issue":"3","key":"1820_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/J.NMD.2018.12.004","volume":"29","author":"LDM Pena","year":"2019","unstructured":"Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, Lafor\u00eat P, Mengel KE et al (2019) Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul Disord. 29(3):167\u2013186. https:\/\/doi.org\/10.1016\/J.NMD.2018.12.004","journal-title":"Neuromuscul Disord."},{"key":"1820_CR32","unstructured":"NCT02782741."},{"issue":"2","key":"1820_CR33","doi-asserted-by":"publisher","first-page":"S49","DOI":"10.1016\/J.YMGME.2014.12.096","volume":"114","author":"R Gotschall","year":"2015","unstructured":"Gotschall R, Xu S, Lun Y et al (2015) Novel recombinant human acid \u03b1-glucosidase with optimal glycosylation is significantly better than standard of care enzyme replacement for glycogen clearance in skeletal muscles of GAA knock-out mice. Mol Genet Metab. 114(2):S49. https:\/\/doi.org\/10.1016\/J.YMGME.2014.12.096","journal-title":"Mol Genet Metab."},{"key":"1820_CR34","doi-asserted-by":"publisher","unstructured":"Xu S, Lun Y, Frascella M et al (2019) Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight 4(5). https:\/\/doi.org\/10.1172\/jci.insight.125358","DOI":"10.1172\/jci.insight.125358"},{"issue":"2","key":"1820_CR35","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/J.YMGME.2018.12.084","volume":"126","author":"PR Clemens","year":"2019","unstructured":"Clemens PR, Mozaffar T, Schoser B et al (2019) Safety and efficacy of advanced and targeted acid \u03b1-glucosidase (AT-GAA) (ATB200\/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial. Mol Genet Metab. 126(2):S40\u2013S41. https:\/\/doi.org\/10.1016\/J.YMGME.2018.12.084","journal-title":"Mol Genet Metab."},{"issue":"2","key":"1820_CR36","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1016\/J.YMGME.2018.12.212","volume":"126","author":"P Kishnani","year":"2019","unstructured":"Kishnani P, Schoser B, Bratkovic D et al (2019) First-in-human study of advanced and targeted acid \u03b1-glucosidase (AT-GAA) (ATB200\/AT2221) in patients with Pompe disease: preliminary functional assessment results from the ATB200-02 trial. Mol Genet Metab. 126(2):S86. https:\/\/doi.org\/10.1016\/J.YMGME.2018.12.212","journal-title":"Mol Genet Metab."},{"issue":"2","key":"1820_CR37","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1016\/J.YMGME.2018.12.340","volume":"126","author":"B Schoser","year":"2019","unstructured":"Schoser B, Bratkovic D, Byrne BJ et al (2019) Preliminary patient-reported outcomes and safety of advanced and targeted acid \u03b1-glucosidase AT-GAA (ATB200\/AT2221) in patients with Pompe disease from the ATB200-02 trial. Mol Genet Metab. 126(2):S132\u2013S133. https:\/\/doi.org\/10.1016\/J.YMGME.2018.12.340","journal-title":"Mol Genet Metab."},{"key":"1820_CR38","unstructured":"NCT03729362."},{"issue":"5","key":"1820_CR39","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s00109-017-1505-9","volume":"95","author":"H Yi","year":"2017","unstructured":"Yi H, Sun T, Armstrong D, Borneman S, Yang C, Austin S, Kishnani PS, Sun B (2017) Antibody-mediated enzyme replacement therapy targeting both lysosomal and cytoplasmic glycogen in Pompe disease. J Mol Med. 95(5):513\u2013521. https:\/\/doi.org\/10.1007\/s00109-017-1505-9","journal-title":"J Mol Med."},{"issue":"2","key":"1820_CR40","doi-asserted-by":"publisher","first-page":"S85","DOI":"10.1016\/J.YMGME.2018.12.211","volume":"126","author":"P Kishnani","year":"2019","unstructured":"Kishnani P, Lachmann R, Mozaffar T et al (2019) Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. Mol Genet Metab. 126(2):S85\u2013S86. https:\/\/doi.org\/10.1016\/J.YMGME.2018.12.211","journal-title":"Mol Genet Metab."},{"issue":"10","key":"1820_CR41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/nrneurol.2013.163","volume":"9","author":"RMN Boustany","year":"2013","unstructured":"Boustany RMN (2013) Lysosomal storage diseases - the horizon expands. Nat Rev Neurol. 9(10):583\u2013598. https:\/\/doi.org\/10.1038\/nrneurol.2013.163","journal-title":"Nat Rev Neurol."},{"issue":"1","key":"1820_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2006.09.010","volume":"90","author":"T Okumiya","year":"2007","unstructured":"Okumiya T, Kroos MA, Van Vliet L, Takeuchi H, Van der Ploeg AT, Reuser AJJ (2007) Chemical chaperones improve transport and enhance stability of mutant \u03b1-glucosidases in glycogen storage disease type II. Mol Genet Metab. 90(1):49\u201357. https:\/\/doi.org\/10.1016\/j.ymgme.2006.09.010","journal-title":"Mol Genet Metab."},{"issue":"5","key":"1820_CR43","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.ymthe.2017.02.017","volume":"25","author":"P Kishnani","year":"2017","unstructured":"Kishnani P, Tarnopolsky M, Roberts M, Sivakumar K, Dasouki M, Dimachkie MM, Finanger E, Goker-Alpan O et al (2017) Duvoglustat HCl increases systemic and tissue exposure of active acid \u03b1-glucosidase in Pompe patients co-administered with alglucosidase \u03b1. Mol Ther. 25(5):1199\u20131208. https:\/\/doi.org\/10.1016\/j.ymthe.2017.02.017","journal-title":"Mol Ther."},{"issue":"23","key":"1820_CR44","doi-asserted-by":"publisher","first-page":"9462","DOI":"10.1021\/acs.jmedchem.7b00646","volume":"60","author":"D D\u2019Alonzo","year":"2017","unstructured":"D\u2019Alonzo D, De Fenza M, Porto C et al (2017) N-butyl-l-deoxynojirimycin (l-NBDNJ): synthesis of an allosteric enhancer of \u03b1-glucosidase activity for the treatment of Pompe disease. J Med Chem. 60(23):9462\u20139469. https:\/\/doi.org\/10.1021\/acs.jmedchem.7b00646","journal-title":"J Med Chem."},{"issue":"10","key":"1820_CR45","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00018-015-1843-0","volume":"72","author":"X Wang","year":"2015","unstructured":"Wang X, Gregory-Evans CY (2015) Nonsense suppression therapies in ocular genetic diseases. Cell Mol Life Sci. 72(10):1931\u20131938. https:\/\/doi.org\/10.1007\/s00018-015-1843-0","journal-title":"Cell Mol Life Sci."},{"key":"1820_CR46","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.mrrev.2014.05.001","volume":"762","author":"JN Miller","year":"2014","unstructured":"Miller JN, Pearce DA (2014) Nonsense-mediated decay in genetic disease: friend or foe? Mutat Res Mutat Res. 762:52\u201364. https:\/\/doi.org\/10.1016\/j.mrrev.2014.05.001","journal-title":"Mutat Res Mutat Res."},{"key":"1820_CR47","doi-asserted-by":"publisher","first-page":"232640981666629","DOI":"10.1177\/2326409816666297","volume":"4","author":"S Ortolano","year":"2016","unstructured":"Ortolano S (2016) Small molecules. J Inborn Errors Metab Screen. 4:232640981666629. https:\/\/doi.org\/10.1177\/2326409816666297","journal-title":"J Inborn Errors Metab Screen."},{"key":"1820_CR48","first-page":"799","volume-title":"Basic & Clinical Pharmacology","author":"DH Deck","year":"2015","unstructured":"Deck DH, Winston LG (2015) Aminoglycosides & spectinomycin. In: Basic & Clinical Pharmacology, pp. 799\u2013806"},{"issue":"1","key":"1820_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.nmd.2012.06.348","volume":"23","author":"KE Birch","year":"2013","unstructured":"Birch KE, Quinlivan RM, Morris GE (2013) Cell models for McArdle disease and aminoglycoside-induced read-through of a premature termination codon. Neuromuscul Disord. 23(1):43\u201351. https:\/\/doi.org\/10.1016\/j.nmd.2012.06.348","journal-title":"Neuromuscul Disord."},{"issue":"4","key":"1820_CR50","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nm0496-467","volume":"2","author":"Marybeth Howard","year":"1996","unstructured":"Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med. 1996;2(4):467-469. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8597960. Accessed May 6, 2019.","journal-title":"Nature Medicine"},{"key":"1820_CR51","unstructured":"Translarna | European Medicines Agency."},{"key":"1820_CR52","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1097\/gme.0b013e3181967b88","volume":"62","author":"JA Becker","year":"1998","unstructured":"Becker JA, Vlach J, Raben N et al (1998) The African origin of the common mutation in African American patients with glycogen-storage disease type II - letters to the editor. Am J Med Genet. 62:991\u2013994. https:\/\/doi.org\/10.1097\/gme.0b013e3181967b88","journal-title":"Am J Med Genet."},{"key":"1820_CR53","unstructured":"What is gene therapy? - Genetics home reference - NIH."},{"issue":"11","key":"1820_CR54","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/humu.23854","volume":"40","author":"Monica Y. Ni\u00f1o","year":"2019","unstructured":"Ni\u00f1o MY, in \u2019t Groen SLM, Bergsma AJ et al (2019) Extension of the Pompe mutation database by linking disease-associated variants to clinical severity. Hum Mutat:humu.23854. https:\/\/doi.org\/10.1002\/humu.23854","journal-title":"Human Mutation"},{"issue":"4","key":"1820_CR55","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1089\/hum.2016.147","volume":"28","author":"A Srivastava","year":"2017","unstructured":"Srivastava A, Carter BJ (2017) AAV Infection: Protection from Cancer. Hum Gene Ther. 28(4):323\u2013327. https:\/\/doi.org\/10.1089\/hum.2016.147","journal-title":"Hum Gene Ther."},{"issue":"1","key":"1820_CR56","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","volume":"11","author":"B Sun","year":"2005","unstructured":"Sun B, Zhang H, Franco LM, Young SP, Schneider A, Bird A, Amalfitano A, Chen YT et al (2005) Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II. Mol Ther. 11(1):57\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2004.10.004","journal-title":"Mol Ther."},{"issue":"2","key":"1820_CR57","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/mt.2012.261","volume":"21","author":"S Benkhelifa-Ziyyat","year":"2013","unstructured":"Benkhelifa-Ziyyat S, Besse A, Roda M, Duque S, Astord S, Carcenac R, Marais T, Barkats M (2013) Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther. 21(2):282\u2013290. https:\/\/doi.org\/10.1038\/mt.2012.261","journal-title":"Mol Ther."},{"issue":"4","key":"1820_CR58","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/mt.2013.282","volume":"22","author":"MK ElMallah","year":"2014","unstructured":"ElMallah MK, Falk DJ, Nayak S et al (2014) Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in Pompe mice. Mol Ther. 22(4):702\u2013712. https:\/\/doi.org\/10.1038\/mt.2013.282","journal-title":"Mol Ther."},{"issue":"2","key":"1820_CR59","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/ana.24433","volume":"78","author":"AG Todd","year":"2015","unstructured":"Todd AG, McElroy JA, Grange RW, Fuller DD, Walter GA, Byrne BJ, Falk DJ (2015) Correcting neuromuscular deficits with gene therapy in Pompe disease. Ann Neurol. 78(2):222\u2013234. https:\/\/doi.org\/10.1002\/ana.24433","journal-title":"Ann Neurol."},{"key":"1820_CR60","doi-asserted-by":"publisher","first-page":"15053","DOI":"10.1038\/mtm.2015.53","volume":"3","author":"PA Doerfler","year":"2016","unstructured":"Doerfler PA, Nayak S, Corti M, Morel L, Herzog RW, Byrne BJ (2016) Targeted approaches to induce immune tolerance for Pompe disease therapy. Mol Ther - Methods Clin Dev. 3:15053. https:\/\/doi.org\/10.1038\/mtm.2015.53","journal-title":"Mol Ther - Methods Clin Dev."},{"issue":"5","key":"1820_CR61","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1089\/104303401300042447","volume":"12","author":"DF Pauly","year":"2002","unstructured":"Pauly DF, Fraites TJ, Toma C et al (2002) Intercellular transfer of the virally derived precursor form of acid \u03b1-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy pompe disease. Hum Gene Ther. 12(5):527\u2013538. https:\/\/doi.org\/10.1089\/104303401300042447","journal-title":"Hum Gene Ther."},{"issue":"5 I","key":"1820_CR62","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1006\/mthe.2002.0580","volume":"5","author":"TJ Fraites","year":"2002","unstructured":"Fraites TJ, Schleissing MR, Shanely RA et al (2002) Correction of the enzymatic and functional deficits in a model of pompe disease using adeno-associated virus vectors. Mol Ther 5(5 I):571\u2013578. https:\/\/doi.org\/10.1006\/mthe.2002.0580","journal-title":"Mol Ther"},{"issue":"14","key":"1820_CR63","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/hmg\/11.14.1637","volume":"11","author":"E. Martin-Touaux","year":"2002","unstructured":"Martin-Touaux E, Puech JP, Ch\u00e2teau D, Emiliani C, Kremer EJ, Raben N, Tancini B, Orlacchio A, Kahn A, Poenaru L Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy. Hum Mol Genet. 2002;11(14):1637-1645. http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12075008. Accessed May 7, 2019.","journal-title":"Human Molecular Genetics"},{"issue":"13","key":"1820_CR64","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1089\/hum.1997.8.13-1555","volume":"8","author":"JZ Zaretsky","year":"1997","unstructured":"Zaretsky JZ, Candotti F, Boerkoel C, Adams EM, Yewdell JW, Blaese RM, Plotz PH (1997) Retroviral transfer of acid alpha-glucosidase cDNA to enzyme-deficient myoblasts results in phenotypic spread of the genotypic correction by both secretion and fusion. Hum Gene Ther. 8(13):1555\u20131563. https:\/\/doi.org\/10.1089\/hum.1997.8.13-1555","journal-title":"Hum Gene Ther."},{"issue":"16","key":"1820_CR65","doi-asserted-by":"publisher","first-page":"8861","DOI":"10.1073\/pnas.96.16.8861","volume":"96","author":"A Amalfitano","year":"2002","unstructured":"Amalfitano A, McVie-Wylie AJ, Hu H, Dawson TL, Raben N, Plotz P, Chen YT (2002) Systemic correction of the muscle disorder glycogen storage disease type II after hepatic targeting of a modified adenovirus vector encoding human acid-glucosidase. Proc Natl Acad Sci. 96(16):8861\u20138866. https:\/\/doi.org\/10.1073\/pnas.96.16.8861","journal-title":"Proc Natl Acad Sci."},{"issue":"4","key":"1820_CR66","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1006\/mthe.2002.0563","volume":"5","author":"E Ding","year":"2002","unstructured":"Ding E, Hu H, Hodges BL, Migone F, Serra D, Xu F, Chen YT, Amalfitano A (2002) Efficacy of gene therapy for a prototypical lysosomal storage disease (GSD-II) is critically dependent on vector dose, transgene promoter, and the tissues targeted for vector transduction. Mol Ther. 5(4):436\u2013446. https:\/\/doi.org\/10.1006\/mthe.2002.0563","journal-title":"Mol Ther."},{"issue":"3","key":"1820_CR67","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/sj.mt.6300100","volume":"15","author":"C Mah","year":"2007","unstructured":"Mah C, Pacak CA, Cresawn KO, Deruisseau LR, Germain S, Lewis MA, Cloutier DA, Fuller DD et al (2007) Physiological correction of pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol Ther. 15(3):501\u2013507. https:\/\/doi.org\/10.1038\/sj.mt.6300100","journal-title":"Mol Ther."},{"issue":"12","key":"1820_CR68","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.1242\/dev.01169","volume":"131","author":"M Rucker","year":"2004","unstructured":"Rucker M, Fraites TJ, Porvasnik SL et al (2004) Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development. 131(12):3007\u20133019. https:\/\/doi.org\/10.1242\/dev.01169","journal-title":"Development."},{"issue":"4","key":"1820_CR69","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/sj.gt.3300609","volume":"5","author":"DF Pauly","year":"1998","unstructured":"Pauly DF, Johns DC, Matelis LA, Lawrence JH, Byrne BJ, Kessler PD (1998) Complete correction of acid alpha-glucosidase deficiency in Pompe disease fibroblasts in vitro, and lysosomally targeted expression in neonatal rat cardiac and skeletal muscle. Gene Ther. 5(4):473\u2013480. https:\/\/doi.org\/10.1038\/sj.gt.3300609","journal-title":"Gene Ther."},{"issue":"1","key":"1820_CR70","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1089\/hum.2005.16.68","volume":"16","author":"KO Cresawn","year":"2005","unstructured":"Cresawn KO, Fraites TJ, Wasserfall C, Atkinson M, Lewis M, Porvasnik S, Liu C, Mah C et al (2005) Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid \u03b1-glucosidase in a model of glycogen storage disease type II. Hum Gene Ther. 16(1):68\u201380. https:\/\/doi.org\/10.1089\/hum.2005.16.68","journal-title":"Hum Gene Ther."},{"issue":"18","key":"1820_CR71","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/sj.gt.3302550","volume":"12","author":"C Mah","year":"2005","unstructured":"Mah C, Cresawn KO, Fraites TJ et al (2005) Sustained correction of glycogen storage disease type II using adeno-associated virus serotype 1 vectors. Gene Ther. 12(18):1405\u20131409. https:\/\/doi.org\/10.1038\/sj.gt.3302550","journal-title":"Gene Ther."},{"issue":"R1","key":"1820_CR72","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","volume":"20","author":"BJ Byrne","year":"2011","unstructured":"Byrne BJ, Falk DJ, Pacak CA, Nayak S, Herzog RW, Elder ME, Collins SW, Conlon TJ et al (2011) Pompe disease gene therapy. Hum Mol Genet. 20(R1):R61\u2013R68. https:\/\/doi.org\/10.1093\/hmg\/ddr174","journal-title":"Hum Mol Genet."},{"key":"1820_CR73","doi-asserted-by":"publisher","unstructured":"Pacak CA, Mah CS, Thattaliyath BD et al (2006) Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 99(4). https:\/\/doi.org\/10.1161\/01.RES.0000237661.18885.f6","DOI":"10.1161\/01.RES.0000237661.18885.f6"},{"issue":"8","key":"1820_CR74","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/mt.2008.133","volume":"16","author":"B Sun","year":"2008","unstructured":"Sun B, Young SP, Li P, di C, Brown T, Salva MZ, Li S, Bird A et al (2008) Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy. Mol Ther. 16(8):1366\u20131371. https:\/\/doi.org\/10.1038\/mt.2008.133","journal-title":"Mol Ther."},{"issue":"3","key":"1820_CR75","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ymthe.2004.01.006","volume":"9","author":"C Mah","year":"2004","unstructured":"Mah C, Fraites TJ, Cresawn KO, Zolotukhin I, Lewis MA, Byrne BJ (2004) A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mol Ther. 9(3):458\u2013463. https:\/\/doi.org\/10.1016\/j.ymthe.2004.01.006","journal-title":"Mol Ther."},{"issue":"3","key":"1820_CR76","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/mt.2009.305","volume":"18","author":"CS Mah","year":"2010","unstructured":"Mah CS, Falk DJ, Germain SA et al (2010) Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol Ther. 18(3):502\u2013510. https:\/\/doi.org\/10.1038\/mt.2009.305","journal-title":"Mol Ther."},{"issue":"2","key":"1820_CR77","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/j.ab.2011.12.026","volume":"421","author":"M Fuller","year":"2012","unstructured":"Fuller M, Duplock S, Turner C, Davey P, Brooks DA, Hopwood JJ, Meikle PJ (2012) Mass spectrometric quantification of glycogen to assess primary substrate accumulation in the Pompe mouse. Anal Biochem. 421(2):759\u2013763. https:\/\/doi.org\/10.1016\/j.ab.2011.12.026","journal-title":"Anal Biochem."},{"issue":"3","key":"1820_CR78","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6","volume":"189","author":"AGA Bijvoet","year":"1999","unstructured":"Bijvoet AGA, Van Hirtum H, Vermey M et al (1999) Pathological features of glycogen storage disease type II highlighted in the knockout mouse model. J Pathol. 189(3):416\u2013424. https:\/\/doi.org\/10.1002\/(SICI)1096-9896(199911)189:3<416::AID-PATH445>3.0.CO;2-6","journal-title":"J Pathol."},{"issue":"2","key":"1820_CR79","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","volume":"189","author":"DD Fuller","year":"2013","unstructured":"Fuller DD, ElMallah MK, Smith BK, Corti M, Lawson LA, Falk DJ, Byrne BJ (2013) The respiratory neuromuscular system in Pompe disease. Respir Physiol Neurobiol. 189(2):241\u2013249. https:\/\/doi.org\/10.1016\/j.resp.2013.06.007","journal-title":"Respir Physiol Neurobiol."},{"issue":"4","key":"1820_CR80","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1002\/ana.20019","volume":"55","author":"LPF Winkel","year":"2004","unstructured":"Winkel LPF, Van den Hout JMP, Kamphoven JHJ et al (2004) Enzyme replacement therapy in late-onset Pompe\u2019s disease: a three-year follow-up. Ann Neurol. 55(4):495\u2013502. https:\/\/doi.org\/10.1002\/ana.20019","journal-title":"Ann Neurol."},{"issue":"23","key":"1820_CR81","doi-asserted-by":"publisher","first-page":"9419","DOI":"10.1073\/pnas.0902534106","volume":"106","author":"LR DeRuisseau","year":"2009","unstructured":"DeRuisseau LR, Fuller DD, Qiu K, DeRuisseau K, Donnelly WH Jr, Mah C, Reier PJ, Byrne BJ (2009) Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc Natl Acad Sci. 106(23):9419\u20139424. https:\/\/doi.org\/10.1073\/pnas.0902534106","journal-title":"Proc Natl Acad Sci."},{"issue":"6","key":"1820_CR82","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/dmcn.13740","volume":"60","author":"Berendine J Ebbink","year":"2018","unstructured":"Ebbink BJ, Poelman E, Aarsen FK et al (2018) Classic infantile Pompe patients approaching adulthood: a cohort study on consequences for the brain. Dev Med Child Neurol. 1. https:\/\/doi.org\/10.1111\/dmcn.13740","journal-title":"Developmental Medicine & Child Neurology"},{"issue":"2","key":"1820_CR83","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","volume":"123","author":"PT Mcintosh","year":"2018","unstructured":"Mcintosh PT, Hobson-webb LD, Kazi ZB et al (2018) Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab. 123(2):85\u201391. https:\/\/doi.org\/10.1016\/j.ymgme.2017.10.005","journal-title":"Mol Genet Metab."},{"issue":"6","key":"1820_CR84","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","volume":"14","author":"B Sun","year":"2006","unstructured":"Sun B, Zhang H, Benjamin DK et al (2006) Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II. Mol Ther. 14(6):822\u2013830. https:\/\/doi.org\/10.1016\/j.ymthe.2006.08.001","journal-title":"Mol Ther."},{"issue":"1","key":"1820_CR85","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/mt.2011.214","volume":"20","author":"K Qiu","year":"2012","unstructured":"Qiu K, Falk DJ, Reier PJ, Byrne BJ, Fuller DD (2012) Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice. Mol Ther. 20(1):21\u201327. https:\/\/doi.org\/10.1038\/mt.2011.214","journal-title":"Mol Ther."},{"issue":"5","key":"1820_CR86","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH (2019) Review therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron. 101(5):839\u2013862. https:\/\/doi.org\/10.1016\/j.neuron.2019.02.017","journal-title":"Neuron."},{"issue":"1","key":"1820_CR87","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymthe.2005.08.006","volume":"13","author":"A Kiang","year":"2006","unstructured":"Kiang A, Hartman ZC, Liao S, Xu F, Serra D, Palmer DJ, Ng P, Amalfitano A (2006) Fully deleted adenovirus persistently expressing GAA accomplishes long-term skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice. Mol Ther. 13(1):127\u2013134. https:\/\/doi.org\/10.1016\/j.ymthe.2005.08.006","journal-title":"Mol Ther."},{"issue":"2","key":"1820_CR88","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1089\/hum.2009.126","volume":"21","author":"AF Tarantal","year":"2010","unstructured":"Tarantal AF, Lee CCI (2010) Long-term luciferase expression monitored by bioluminescence imaging after adeno-associated virus-mediated fetal gene delivery in rhesus monkeys (Macaca mulatta). Hum Gene Ther. 21(2):143\u2013148. https:\/\/doi.org\/10.1089\/hum.2009.126","journal-title":"Hum Gene Ther."},{"issue":"4","key":"1820_CR89","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ymthe.2004.07.016","volume":"10","author":"MJ Blankinship","year":"2004","unstructured":"Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Chamberlain JS (2004) Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Mol Ther. 10(4):671\u2013678. https:\/\/doi.org\/10.1016\/j.ymthe.2004.07.016","journal-title":"Mol Ther."},{"issue":"9","key":"1820_CR90","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/mt.2013.96","volume":"21","author":"DJ Falk","year":"2013","unstructured":"Falk DJ, Mah CS, Soustek MS, Lee KZ, Elmallah MK, Cloutier DA, Fuller DD, Byrne BJ (2013) Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease. Mol Ther. 21(9):1661\u20131667. https:\/\/doi.org\/10.1038\/mt.2013.96","journal-title":"Mol Ther."},{"issue":"3","key":"1820_CR91","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/hmg\/ddu476","volume":"24","author":"DJ Falk","year":"2015","unstructured":"Falk DJ, Todd AG, Lee S et al (2015) Peripheral nerve and neuromuscular junction pathology in Pompe disease. Hum Mol Genet. 24(3):625\u2013636. https:\/\/doi.org\/10.1093\/hmg\/ddu476","journal-title":"Hum Mol Genet."},{"issue":"4","key":"1820_CR92","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/humc.2016.119","volume":"27","author":"TJ Conlon","year":"2016","unstructured":"Conlon TJ, Mah CS, Pacak CA, Rucker Henninger MB, Erger KE, Jorgensen ML, Lee CC, Tarantal AF et al (2016) Transfer of therapeutic genes into fetal rhesus monkeys using recombinant adeno-associated type I viral vectors. Hum Gene Ther Clin Dev. 27(4):152\u2013159. https:\/\/doi.org\/10.1089\/humc.2016.119","journal-title":"Hum Gene Ther Clin Dev."},{"key":"1820_CR93","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1479-0556-6-13","volume":"6","author":"CA Pacak","year":"2008","unstructured":"Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ (2008) Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther. 6:13. https:\/\/doi.org\/10.1186\/1479-0556-6-13","journal-title":"Genet Vaccines Ther."},{"issue":"1","key":"1820_CR94","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/hum.2018.016","volume":"30","author":"Allison M. Keeler","year":"2019","unstructured":"Keeler AM, Zieger M, Todeasa SH et al (2018) Systemic Delivery of AAVB1- GAA clears glycogen and prolongs survival in a mouse model of Pompe disease. Hum Gene Ther:hum.2018.016. https:\/\/doi.org\/10.1089\/hum.2018.016","journal-title":"Human Gene Therapy"},{"issue":"1","key":"1820_CR95","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nbt.1515","volume":"27","author":"KD Foust","year":"2009","unstructured":"Foust KD, Nurre E, Montgomery CL, Hernandez A, Chan CM, Kaspar BK (2009) Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol. 27(1):59\u201365. https:\/\/doi.org\/10.1038\/nbt.1515","journal-title":"Nat Biotechnol."},{"issue":"4","key":"1820_CR96","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1089\/hum.2011.200","volume":"23","author":"L Samaranch","year":"2012","unstructured":"Samaranch L, Salegio EA, San Sebastian W, Kells AP, Foust KD, Bringas JR, Lamarre C, Forsayeth J et al (2012) Adeno-associated virus serotype 9 transduction in the central nervous system of nonhuman primates. Hum Gene Ther. 23(4):382\u2013389. https:\/\/doi.org\/10.1089\/hum.2011.200","journal-title":"Hum Gene Ther."},{"issue":"1","key":"1820_CR97","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/gt.2009.119","volume":"17","author":"C Towne","year":"2010","unstructured":"Towne C, Schneider BL, Kieran D, Redmond DE, Aebischer P (2010) Efficient transduction of non-human primate motor neurons after intramuscular delivery of recombinant AAV serotype 6. Gene Ther. 17(1):141\u2013146. https:\/\/doi.org\/10.1038\/gt.2009.119","journal-title":"Gene Ther."},{"issue":"5634","key":"1820_CR98","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1126\/science.1086137","volume":"301","author":"BK Kaspar","year":"2003","unstructured":"Kaspar BK, Llad\u00f3 J, Sherkat N, Rothstein JD, Gage FH (2003) Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (80- ) 301(5634):839\u2013842. https:\/\/doi.org\/10.1126\/science.1086137","journal-title":"Science (80- )"},{"issue":"5","key":"1820_CR99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064755","volume":"8","author":"HM Gransee","year":"2013","unstructured":"Gransee HM, Zhan W-Z, Sieck GC, Mantilla CB (2013) Targeted delivery of TrkB receptor to phrenic motoneurons enhances functional recovery of rhythmic phrenic activity after cervical spinal hemisection. PLoS One. 8(5):e64755. https:\/\/doi.org\/10.1371\/journal.pone.0064755","journal-title":"PLoS One."},{"issue":"23","key":"1820_CR100","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/sj.gt.3301829","volume":"9","author":"K Yuasa","year":"2002","unstructured":"Yuasa K, Sakamoto M, Miyagoe-Suzuki Y, Tanouchi A, Yamamoto H, Li J, Chamberlain JS, Xiao X et al (2002) Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. 9(23):1576\u20131588. https:\/\/doi.org\/10.1038\/sj.gt.3301829","journal-title":"Gene Ther."},{"issue":"8","key":"1820_CR101","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1085","volume":"10","author":"P Gregorevic","year":"2004","unstructured":"Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat Med. 10(8):828\u2013834. https:\/\/doi.org\/10.1038\/nm1085","journal-title":"Nat Med."},{"issue":"11","key":"1820_CR102","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/jgm.1511","volume":"12","author":"B Sun","year":"2010","unstructured":"Sun B, Li S, Bird A, Yi H, Kemper A, Thurberg BL, Koeberl DD (2010) Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease. J Gene Med. 12(11):881\u2013891. https:\/\/doi.org\/10.1002\/jgm.1511","journal-title":"J Gene Med."},{"issue":"3","key":"1820_CR103","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1084\/jem.169.3.779","volume":"169","author":"SX Qin","year":"1989","unstructured":"Qin SX, Cobbold S, Benjamin R, Waldmann H (1989) Induction of classical transplantation tolerance in the adult. J Exp Med. 169(3):779\u2013794","journal-title":"J Exp Med."},{"issue":"23","key":"1820_CR104","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","volume":"89","author":"E Kuperus","year":"2017","unstructured":"Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden J, Rizopoulos D, Brusse E et al (2017) Long-term benefit of enzyme replacement therapy in Pompe disease: a 5-year prospective study. Neurology. 89(23):2365\u20132373. https:\/\/doi.org\/10.1212\/WNL.0000000000004711","journal-title":"Neurology."},{"issue":"1","key":"1820_CR105","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1089\/hum.2014.115","volume":"26","author":"S Han","year":"2015","unstructured":"Han S, Li S, Brooks ED, Masat E, Leborgne C, Banugaria S, Bird A, Mingozzi F et al (2015) Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade. Hum Gene Ther. 26(1):26\u201335. https:\/\/doi.org\/10.1089\/hum.2014.115","journal-title":"Hum Gene Ther."},{"issue":"6","key":"1820_CR106","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","volume":"11","author":"B Sun","year":"2005","unstructured":"Sun B, Zhang H, Franco LM, Brown T, Bird A, Schneider A, Koeberl DD (2005) Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter. Mol Ther. 11(6):889\u2013898. https:\/\/doi.org\/10.1016\/j.ymthe.2005.01.012","journal-title":"Mol Ther."},{"issue":"12","key":"1820_CR107","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/eji.1830201231","volume":"20","author":"S Qin","year":"1990","unstructured":"Qin S, Wise M, Cobbold SP et al (1990) Induction of tolerance in peripheral T cells with monoclonal antibodies. Eur J Immunol. 20(12):2737\u20132745. https:\/\/doi.org\/10.1002\/eji.1830201231","journal-title":"Eur J Immunol."},{"issue":"6061","key":"1820_CR108","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/320449a0","volume":"320","author":"RJ Benjamin","year":"1986","unstructured":"Benjamin RJ, Waldmann H (1986) Induction of tolerance by monoclonal antibody therapy. Nature. 320(6061):449\u2013451. https:\/\/doi.org\/10.1038\/320449a0","journal-title":"Nature."},{"issue":"11","key":"1820_CR109","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1136\/ard.2003.013060","volume":"63","author":"K Nissler","year":"2004","unstructured":"Nissler K, Pohlers D, H\u00fcckel M, Simon J, Br\u00e4uer R, Kinne RW (2004) Anti-CD4 monoclonal antibody treatment in acute and early chronic antigen induced arthritis: influence on macrophage activation. Ann Rheum Dis. 63(11):1470\u20131477. https:\/\/doi.org\/10.1136\/ard.2003.013060","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"1820_CR110","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1182\/blood-2004-10-3888","volume":"105","author":"M Karim","year":"2005","unstructured":"Karim M, Feng G, Wood KJ, Bushell AR (2005) CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: antigen-specific reactivation in vivo is critical for bystander regulation. Blood. 105(12):4871\u20134877. https:\/\/doi.org\/10.1182\/blood-2004-10-3888","journal-title":"Blood."},{"key":"1820_CR111","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.ymgmr.2014.08.005","volume":"1","author":"B Sun","year":"2014","unstructured":"Sun B, Banugaria SG, Prater SN, Patel TT, Fredrickson K, Ringler DJ, de Fougerolles A, Rosenberg AS et al (2014) Non-depleting anti-CD4 monoclonal antibody induces immune tolerance to ERT in a murine model of Pompe disease. Mol Genet Metab Reports. 1:446\u2013450. https:\/\/doi.org\/10.1016\/j.ymgmr.2014.08.005","journal-title":"Mol Genet Metab Reports."},{"issue":"21","key":"1820_CR112","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1038\/sj.gt.3302314","volume":"11","author":"F Xu","year":"2004","unstructured":"Xu F, Ding E, Liao SX, Migone F, Dai J, Schneider A, Serra D, Chen YT et al (2004) Improved efficacy of gene therapy approaches for Pompe disease using a new, immune-deficient GSD-II mouse model. Gene Ther. 11(21):1590\u20131598. https:\/\/doi.org\/10.1038\/sj.gt.3302314","journal-title":"Gene Ther."},{"key":"1820_CR113","doi-asserted-by":"publisher","first-page":"103737","DOI":"10.1016\/j.cellimm.2017.12.011","volume":"342","author":"J.E. Bond","year":"2019","unstructured":"Bond JE, Kishnani PS, Koeberl DD (December 2017) Immunomodulatory, liver depot gene therapy for Pompe disease. Cell Immunol. https:\/\/doi.org\/10.1016\/j.cellimm.2017.12.011","journal-title":"Cellular Immunology"},{"key":"1820_CR114","doi-asserted-by":"publisher","unstructured":"Puzzo F, Colella P, Biferi MG et al (2017) Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase. Sci Transl Med 9(418). https:\/\/doi.org\/10.1126\/scitranslmed.aam6375.Rescue","DOI":"10.1126\/scitranslmed.aam6375.Rescue"},{"issue":"5","key":"1820_CR115","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1086\/522236","volume":"81","author":"B Sun","year":"2007","unstructured":"Sun B, Bird A, Young SP, Kishnani PS, Chen Y-T, Koeberl DD (2007) Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet. 81(5):1042\u20131049. https:\/\/doi.org\/10.1086\/522236","journal-title":"Am J Hum Genet."},{"issue":"December 2016","key":"1820_CR116","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","volume":"4","author":"S Han","year":"2017","unstructured":"Han S, Ronzitti G, Arnson B, Leborgne C, Li S, Mingozzi F, Koeberl D (2017) Low-dose liver-targeted gene therapy for Pompe disease enhances therapeutic efficacy of ERT via immune tolerance induction. Mol Ther Methods Clin Dev. 4(December 2016):126\u2013136. https:\/\/doi.org\/10.1016\/j.omtm.2016.12.010","journal-title":"Mol Ther Methods Clin Dev."},{"key":"1820_CR117","doi-asserted-by":"publisher","first-page":"15007","DOI":"10.1038\/mtm.2015.7","volume":"2","author":"DJ Falk","year":"2015","unstructured":"Falk DJ, Soustek MS, Todd AG, Mah CS, Cloutier DA, Kelley JS, Clement N, Fuller DD et al (2015) Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice. Mol Ther - Methods Clin Dev. 2:15007. https:\/\/doi.org\/10.1038\/mtm.2015.7","journal-title":"Mol Ther - Methods Clin Dev."},{"issue":"4","key":"1820_CR118","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1089\/humc.2017.146","volume":"28","author":"M Corti","year":"2017","unstructured":"Corti M, Liberati C, Smith BK, Lawson LA, Tuna IS, Conlon TJ, Coleman KE, Islam S et al (2017) Safety of intradiaphragmatic delivery of adeno-associated virus-mediated alpha-glucosidase (rAAV1-CMV-hGAA) gene therapy in children affected by Pompe disease. Hum Gene Ther Clin Dev. 28(4):208\u2013218. https:\/\/doi.org\/10.1089\/humc.2017.146","journal-title":"Hum Gene Ther Clin Dev."},{"issue":"6","key":"1820_CR119","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1089\/hum.2012.250","volume":"24","author":"BK Smith","year":"2013","unstructured":"Smith BK, Collins SW, Conlon TJ, Mah CS, Lawson LA, Martin AD, Fuller DD, Cleaver BD et al (2013) Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 24(6):630\u2013640. https:\/\/doi.org\/10.1089\/hum.2012.250","journal-title":"Hum Gene Ther."},{"issue":"Pt 2","key":"1820_CR120","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","volume":"287","author":"BK Smith","year":"2017","unstructured":"Smith BK, Martin AD, Lawson LA, Vernot V, Marcus J, Islam S, Shafi N, Corti M et al (2017) Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: clinical evidence of respiratory plasticity. Exp Neurol. 287(Pt 2):216\u2013224. https:\/\/doi.org\/10.1016\/j.expneurol.2016.07.013","journal-title":"Exp Neurol."},{"issue":"3","key":"1820_CR121","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1089\/humc.2014.2514","volume":"25","author":"BJ Byrne","year":"2014","unstructured":"Byrne BJ, Smith B, Mah C et al (2014) Phase I\/II Trial of Diaphragm Delivery of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV1-CMV- GAA) gene vector in patients with Pompe disease. Hum Gene Ther Clin Dev. 25(3):134\u2013163. https:\/\/doi.org\/10.1089\/humc.2014.2514","journal-title":"Hum Gene Ther Clin Dev."},{"issue":"2","key":"1820_CR122","doi-asserted-by":"publisher","first-page":"ppul.24203","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2018","unstructured":"Al-Zaidy S, Pickard AS, Kotha K et al (2018) Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol 54(2):ppul.24203. https:\/\/doi.org\/10.1002\/ppul.24203","journal-title":"Pediatr Pulmonol"},{"key":"1820_CR123","unstructured":"NCT02240407."},{"key":"1820_CR124","doi-asserted-by":"publisher","unstructured":"Calcedo R, Wilson JM (2013) Humoral Immune Response to AAV. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2013.00341","DOI":"10.3389\/fimmu.2013.00341"},{"issue":"85","key":"1820_CR125","first-page":"379","volume":"15","author":"E Masat","year":"2013","unstructured":"Masat E, Pavani G, Mingozzi F (2013) Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med. 15(85):379\u2013389","journal-title":"Discov Med."},{"issue":"3","key":"1820_CR126","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1089\/humc.2015.068","volume":"26","author":"M Corti","year":"2015","unstructured":"Corti M, Cleaver B, Cl\u00e9ment N et al (2015) Evaluation of readministration of a recombinant adeno-associated virus vector expressing acid alpha-glucosidase in Pompe disease: preclinical to clinical planning. Hum Gene Ther Clin Dev. 26(3):185\u2013193. https:\/\/doi.org\/10.1089\/humc.2015.068","journal-title":"Hum Gene Ther Clin Dev."},{"key":"1820_CR127","doi-asserted-by":"publisher","first-page":"15023","DOI":"10.1038\/mtm.2015.23","volume":"2","author":"Y Sato","year":"2015","unstructured":"Sato Y, Kobayashi H, Higuchi T et al (2015) Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient. Mol Ther - Methods Clin Dev. 2:15023. https:\/\/doi.org\/10.1038\/mtm.2015.23","journal-title":"Mol Ther - Methods Clin Dev."},{"issue":"4","key":"1820_CR128","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/gt.2009.160","volume":"17","author":"SO Kyosen","year":"2010","unstructured":"Kyosen SO, Iizuka S, Kobayashi H, Kimura T, Fukuda T, Shen J, Shimada Y, Ida H et al (2010) Neonatal gene transfer using lentiviral vector for murine Pompe disease: long-term expression and glycogen reduction. Gene Ther. 17(4):521\u2013530. https:\/\/doi.org\/10.1038\/gt.2009.160","journal-title":"Gene Ther."},{"issue":"8","key":"1820_CR129","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/hum.2015.070","volume":"26","author":"KE Lundin","year":"2015","unstructured":"Lundin KE, Gissberg O, Smith CIE (2015) Oligonucleotide Therapies: The Past and the Present. Hum Gene Ther. 26(8):475\u2013485. https:\/\/doi.org\/10.1089\/hum.2015.070","journal-title":"Hum Gene Ther."},{"key":"1820_CR130","doi-asserted-by":"publisher","unstructured":"Miller CM, Harris EN Antisense oligonucleotides: treatment strategies and cellular internalization. RNA Dis (Houston, Tex), 2016 3(4). https:\/\/doi.org\/10.14800\/rd.1393","DOI":"10.14800\/rd.1393"},{"issue":"2","key":"1820_CR131","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/nrd3625","volume":"11","author":"R Kole","year":"2012","unstructured":"Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov. 11(2):125\u2013140. https:\/\/doi.org\/10.1038\/nrd3625","journal-title":"Nat Rev Drug Discov."},{"issue":"9","key":"1820_CR132","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/J.YMTHE.2017.05.019","volume":"25","author":"E Goina","year":"2017","unstructured":"Goina E, Peruzzo P, Bembi B, Dardis A, Buratti E (2017) Glycogen reduction in myotubes of late-onset Pompe disease patients using antisense technology. Mol Ther. 25(9):2117\u20132128. https:\/\/doi.org\/10.1016\/J.YMTHE.2017.05.019","journal-title":"Mol Ther."},{"issue":"June","key":"1820_CR133","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.omtn.2017.03.002","volume":"7","author":"E van der Wal","year":"2017","unstructured":"van der Wal E, Bergsma AJ, van Gestel TJM, in 't Groen SLM, Zaehres H, Ara\u00fazo-Bravo MJ, Sch\u00f6ler HR, van der Ploeg A et al (2017) GAA Deficiency in Pompe disease is alleviated by exon inclusion in iPSC-derived skeletal muscle cells. Mol Ther-Nucleic Acids. 7(June):101\u2013115. https:\/\/doi.org\/10.1016\/j.omtn.2017.03.002","journal-title":"Mol Ther-Nucleic Acids."},{"issue":"June","key":"1820_CR134","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.omtn.2017.03.001","volume":"7","author":"E van der Wal","year":"2017","unstructured":"van der Wal E, Bergsma AJ, Pijnenburg JM, van der Ploeg AT, Pijnappel WWMP (2017) Antisense oligonucleotides promote exon inclusion and correct the common c.-32-13T>G GAA splicing variant in Pompe disease. Mol Ther-Nucleic Acids. 7(June):90\u2013100. https:\/\/doi.org\/10.1016\/j.omtn.2017.03.001","journal-title":"Mol Ther-Nucleic Acids."},{"key":"1820_CR135","volume-title":"The online metabolic and molecular basis of inherited disease","author":"R Hirschhorn","year":"2001","unstructured":"Hirschhorn R (2001) Pompe Disease. In: The online metabolic and molecular basis of inherited disease"},{"issue":"5","key":"1820_CR136","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1590\/0004-282X20130022","volume":"71","author":"LC Werneck","year":"2013","unstructured":"Werneck LC, Lorenzoni PJ, Kay CSK et al (2013) Muscle biopsy in Pompe disease. Arq Neuropsiquiatr. 71(5):284\u2013289. https:\/\/doi.org\/10.1590\/0004-282X20130022","journal-title":"Arq Neuropsiquiatr."},{"issue":"12","key":"1820_CR137","doi-asserted-by":"publisher","first-page":"ddw118","DOI":"10.1093\/hmg\/ddw118","volume":"25","author":"A Garanto","year":"2016","unstructured":"Garanto A, Chung DC, Duijkers L et al (2016) In vitro and in vivo rescue of aberrant splicing in CEP290-associated LCA by antisense oligonucleotide delivery. Hum Mol Genet 25(12):ddw118. https:\/\/doi.org\/10.1093\/hmg\/ddw118","journal-title":"Hum Mol Genet"},{"key":"1820_CR138","doi-asserted-by":"publisher","unstructured":"Raben N, Wong A, Ralston E, Myerowitz R (2012) Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten. Am J Med Genet C Semin Med Genet. https:\/\/doi.org\/10.1080\/10810730902873927.Testing","DOI":"10.1080\/10810730902873927.Testing"},{"issue":"2","key":"1820_CR139","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","volume":"11","author":"J-A Lim","year":"2015","unstructured":"Lim J-A, Li L, Kakhlon O, Myerowitz R, Raben N (2015) Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy. 11(2):385\u2013402. https:\/\/doi.org\/10.1080\/15548627.2015.1009779","journal-title":"Autophagy."},{"issue":"3","key":"1820_CR140","doi-asserted-by":"publisher","first-page":"353","DOI":"10.15252\/emmm.201606547","volume":"9","author":"J-A Lim","year":"2017","unstructured":"Lim J-A, Li L, Shirihai OS, Trudeau KM, Puertollano R, Raben N (2017) Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO Mol Med 9(3):353\u2013370. https:\/\/doi.org\/10.15252\/emmm.201606547","journal-title":"EMBO Mol Med"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01820-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-019-01820-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-019-01820-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T01:09:16Z","timestamp":1605056956000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-019-01820-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":140,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1007\/s12035-019-01820-5","relation":{},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"26 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}